TTK and cancer: Several small‐molecule inhibitors targeting TTK have been developed and characterized for cancer treatment.[31, 32, 33] Among these, three inhibitors have undergone clinical trials, with CFI‐402257 currently in phase 2 clinical trials (NCT05251714).